番茄社区

Charles Bankhead

Charles Bankhead

Authors >

Charles Bankhead

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. His career spans more than 30 years, including a decade with Medical World News, a leading medical trade magazine of its time. He had a long and successful freelance career before joining 番茄社区 in 2007. Charles graduated with honors from Texas Tech University, receiving a BA in journalism, and completed a master's degree in mass communication, with specialization in health communication, also at Texas Tech.

Connect:

email image

Latest from Charles Bankhead

ACG over a photo of the Henry B. Gonzalez Convention Center, San Antonio, TX

Constipation in Older Adults Improved With Biofeedback

Small retrospective study extends efficacy observed in younger patients

ACG over a photo of the Henry B. Gonzalez Convention Center, San Antonio, TX

Human Milk Sugars Quell IBS Symptoms

Bowel function, pain, bloating improved by 50% within a month with nonprescription supplement

ACG over a photo of the Henry B. Gonzalez Convention Center, San Antonio, TX

Eosinophilic Esophagitis Responds to Steroid

Majority of previously treated patients responded to oral formulation of topical budesonide

Fall Derm over a photo of the Wynn, Las Vegas, NV

JAK Inhibitors Emerging as Oral Option for Psoriasis

But older oral therapies remain key therapeutic players for many patients

Fall Derm over a photo of the Wynn, Las Vegas, NV

Chronic Itch: New Therapy, Complexities

"End of the antihistamine era" as new strategies target neural mechanisms

AAO over a photo of the Moscone Center in San Francisco, CA

Conjugate Active in Exudative Retinal Diseases

Improved vision, decreased retinal thickening with antibody-biopolymer agent

ESMO over a photo of FIRA Barcelona, Spain

First-Line Combo Boosts PFS in Untreated Bladder Cancer

'Clinically meaningful' trend in OS with atezolizumab-chemotherapy

ESMO over a photo of FIRA Barcelona, Spain

Neoadjuvant Anti-PD-1 Boosts pCR in TNBC

Favorable trend toward improved event-free survival in preliminary analysis

ESMO over a photo of FIRA Barcelona, Spain

Data Support 'Best Drug First' in EGFR-Mutant NSCLC

Six-month survival gain with osimertinib, adding to PFS, safety advantages

ESMO over a photo of FIRA Barcelona, Spain

First-Line Combo Boosts PFS in Advanced Ovarian Ca

Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup

鈥�

82

鈥�